Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Incyte Corp's new chief executive, Bill Meury, outlined a growth strategy on Tuesday focused on accelerating drug development and prudent capital allocation, as the company faces the looming patent ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

Chewy Inc. CHWY delivered a strong and well-rounded performance across all major segments in the first quarter of fiscal 2025. Net sales rose 8.3% year over year to $3.12 billion, exceeding the high ...

Charta Health built an artificial-intelligence-powered platform to optimize medical billing and coding. The three-year-old ...

Chewy will not receive any proceeds from this offering. Meanwhile, JMP Securities and Citizens JMP have both raised their price targets for Chewy to $48, citing the company’s strong core business and ...

The integration of healthcare services with Chewy’s existing e-commerce platform could create a comprehensive ecosystem for pet owners, further solidifying Chewy’s market position.

However, analysts remain optimistic about the company’s long-term margin expansion potential, driven by initiatives in pet healthcare, private label products, and advertising revenue. Growth ...

As the pet industry continues to evolve, Chewy’s strategic initiatives and market positioning have garnered significant attention from investors and analysts alike. This comprehensive analysis ...

As the pet industry continues to evolve, Chewy’s strategic initiatives and market positioning have garnered significant attention from investors and analysts alike. This comprehensive analysis ...